# A Randomized, Double-masked, Multicenter, Controlled Study of Intravitreal KH902 in Patients With Neovascular AMD

> **NCT01157715** · PHASE2 · COMPLETED · sponsor: **Chengdu Kanghong Biotech Co., Ltd.** · enrollment: 122 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **BIOLOGICAL:** intravitreal injection of KH902

## Key facts

- **NCT ID:** NCT01157715
- **Lead sponsor:** Chengdu Kanghong Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2012-01
- **Final completion:** 2012-07
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2014-11-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01157715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01157715, "A Randomized, Double-masked, Multicenter, Controlled Study of Intravitreal KH902 in Patients With Neovascular AMD". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01157715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*